Zobrazeno 1 - 10
of 167
pro vyhledávání: ''
Autor:
Sudeep Banerjee, Robert J. Wechsler-Reya, Jill P. Mesirov, Alexander T. Wenzel, Hyunho Yoon, Huwate Yeerna, Chih-Min Tang, Mayra Yebra, Pablo Tamayo, Stephanie Ting, Jason K. Sicklick
Publikováno v:
Molecular Cancer Therapeutics. 20:2035-2048
Gastrointestinal stromal tumor (GIST) is commonly driven by oncogenic KIT mutations that are effectively targeted by imatinib (IM), a tyrosine kinase inhibitor (TKI). However, IM does not cure GIST, and adjuvant therapy only delays recurrence in high
Autor:
Lei Bi, Fuqiong Zhou, Peng Meng, Bo Tang, Yidan Ren, Yunshan Wang, Yu-Cui Jiang, Weiping Chen, Qin Wang, Chuanxin Wang, Maoxiao Feng, Yuli Wang, Feiyan Chen, Qinlian Jiao, Lutao Du
Publikováno v:
Cancer Research. 81:2015-2028
Hepatocellular carcinoma (HCC) contains a subset of cancer stem cells (CSC) that cause tumor recurrence, metastasis, and chemical resistance. Histone deacetylase 11 (HDAC11) mediates diverse immune functions and metabolism, yet little is known about
Autor:
Dongsheng Tu, Timothy J. Price, Hagen F. Kennecke, Daniel L. Edelstein, Scott Kopetz, Frank Holtrup, Hannah Quinn, Anthony Dowers, Stanley R. Hamilton, Derek J. Jonker, John Zalcberg, Christos S Karapetis, Paul Waring, Jonathan M. Loree, Christopher J. O'Callaghan, Malcolm J. Moore
Publikováno v:
Clinical Cancer Research. 27:52-59
Purpose: Expanded RAS/BRAF mutations have not been assessed as predictive for single-agent cetuximab in metastatic colorectal cancer (mCRC), and low mutant allele frequency (MAF) mutations are of unclear significance. We aimed to establish cetuximab
Autor:
Richard Price, Christine Ju, Johanna C. Bendell, Herbert Hurwitz, Xiaoju Max Ma, John Lee, Nalin Tikoo, Christoph Mancao, Lijing Yao, Alex Lovejoy, Alan Nicholas, Stephanie J. Yaung, John F. Palma, Nicolas Sommer
Publikováno v:
Clinical Cancer Research. 26:4010-4017
Purpose:We assessed plasma circulating tumor DNA (ctDNA) level as a prognostic marker for progression-free survival (PFS) following first-line metastatic colorectal cancer (mCRC) therapy.Experimental Design:The Sequencing Triplet With Avastin and Mai
Autor:
Weiwei Jin, Lianpeng Chang, Song Ye, Jiahong Jiang, Huaixiang Zhou, Yaping Xu, Liu Yang, Xiaoge Hu, Chao Ni
Publikováno v:
Molecular Cancer Therapeutics. 19:956-965
With the increase of treatment course, resistance to EGFR blockade is inevitable in patients with metastatic colorectal cancer (mCRC). KRAS mutations have been considered to be primary drivers of this resistance; however, the potential function of ot
Autor:
Genta Nagae, Kazuhiko Koike, Hayato Nakagawa, Yutaka Midorikawa, Shogo Yamamoto, Kenji Tatsuno, Kyoji Moriya, Tadatoshi Takayama, Mitsuhiko Moriyama, Hiroyuki Aburatani
Publikováno v:
Clinical Cancer Research. 25:6217-6227
Purpose:Hepatitis B viral (HBV) DNA is frequently integrated into the genomes of hepatocellular carcinoma (HCC) in patients with chronic HBV infection (chronic HBV, hereafter), whereas the frequency of HBV integration in patients after the disappeara
Publikováno v:
Clinical Cancer Research. 25:4141-4154
Purpose: Hepatocellular carcinoma (HCC), one of the most common and deadliest malignancies worldwide, has a poor prognosis, owing to its high potential for vascular invasion and metastasis and the lack of biomarkers for early diagnosis. Thus, it must
Autor:
Vinod Ganju, M. Karthaus, Alessio Amatu, Andrea Pirzkall, Amy V. Kapp, Michael Findlay, Maria Di Bartolomeo, Leslie Samuel, Manuel Hidalgo, Bruce McCall, Christopher Jackson, Roxana Ioana Sufan, Andrew L. Coveler, William D. Hanley, John Bridgewater, Matthew Burge, Elicia Penuel, Pilar García Alfonso, Andrew G. Hill, Josep Tabernero, Mark Jeffery
Publikováno v:
Clinical Cancer Research. 24:2276-2284
Purpose: Duligotuzumab is a dual-action antibody directed against EGFR and HER3. Experimental Design: Metastatic colorectal cancer (mCRC) patients with KRAS ex2 wild-type received duligotuzumab or cetuximab and FOLFIRI until progression or intolerabl
Autor:
Jamie J. Shah, Francis Y. Lee, Bruce S. Fischer, Hossein Khiabanian, Sharon R. Pine, Joseph R. Bertino, Katherine M. Morgan, Amartya Singh, Jeffrey A. Rosenfeld
Publikováno v:
Molecular Cancer Therapeutics. 16:2759-2769
Notch signaling is aberrantly activated in approximately one third of non–small cell lung cancers (NSCLC). We characterized the interaction between BMS-906024, a clinically relevant Notch gamma secretase inhibitor, and front-line chemotherapy in pr
Autor:
Amit Aggarwal, Gregory P. Donoho, Gregory D. Plowman, Ramon V. Tiu, Robert D. Van Horn, Sheng Bin Peng, Youyan Zhang, Jason C. Ting, Ruslan D. Novosiadly, Yue Webster, Yung Mae M. Yao, Amelie Forest, Philip W. Iversen, Henry James Robert, Philip J. Ebert, Steven M. Bray
Publikováno v:
Clinical Cancer Research. 23:5547-5560
Purpose: To evaluate the antitumor efficacy of cetuximab in combination with LSN3074753, an analog of LY3009120 and pan-RAF inhibitor in 79 colorectal cancer patient-derived xenograft (PDX) models. Experimental Design: Seventy-nine well-characterized